Leading State Life Sciences Associations Express Concerns with CMS’ Rule on Medicaid Value-Based Agreements

BioNJ, Biocom, the California Life Sciences Association, the HINJ, LSPA, and the Michigan Biosciences Industry Association submitted comments to the CMS on a notice of proposed rulemaking impacting value-based purchasing agreements and other innovative solutions designed to provide patient access to, and purchasing agreements for, cutting edge therapies and cures.

July 20, 2020 21:46 UTC

SAN DIEGO & LOS ANGELES & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- BioNJ, Biocom, the California Life Sciences Association (CLSA), the HealthCare Institute of New Jersey (HINJ), Life Sciences Pennsylvania (LSPA), and the Michigan Biosciences Industry Association (MichBio) today submitted comments to the Centers for Medicare and Medicaid Services (CMS) on a notice of proposed rulemaking (NPRM) impacting value-based purchasing (VBP) agreements and other innovative solutions designed to provide patient access to, and purchasing agreements for, cutting edge therapies and cures.

While commending CMS’ actions designed to streamline manufacturer VBP agreements and ease their use for greater patient access, the associations asked that CMS provide additional clarity regarding the methods through which manufacturers might operationalize these provisions. The letter also expressed concerns with the NPRM’s proposals on copay “accumulators” and definitions for new formularies and line extensions since manufacturers do not control or have meaningful input into health plan benefit designs. Additionally, the associations shared concerns that these provisions could unnecessarily increase Patient costs at the pharmacy counter.

In a joint statement by the six associations’ CEOs, the letter specifies that “Despite our appreciation for CMS’ efforts to improve the capabilities of manufacturers to implement value-based arrangements, we have significant concerns with the NPRM’s changes to how copay cards are calculated for purposes of best price, and efforts to expand the definition of line extension. As proposed by CMS, both of these changes meaningfully depart from statutory intent, may significantly harm Patient access to critical copay assistance, and negatively impact future innovation.”

Comments on the NPRM are due Monday, July 20. A copy of the letter can be found here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005802/en/

Contacts

Biocom
Carolyn Hawley | Canale Communications
Carolyn@canalecomm.com | 619-849-5382

BioNJ
Randi Bromberg | Vice President, Marketing and Communications
RBromber@BioNJ.org | 609-955-1067

California Life Sciences Association (CLSA)
Oliver Rocroi | Vice President, Communications & External Affairs
orocroi@califesciences.org | 916-588-0965

HealthCare Institute of New Jersey (HINJ)
Allison Freeman | Director, Communications
afreeman@hinj.org | 973-769-6614

Life Sciences Pennsylvania (LSPA)
Kurt Imhof | Vice President, Policy & Public Affairs
kimhof@lifesciencespa.org | 610.947.6800 x. 21

Michigan Biosciences Industry Association (MichBio)
Alisha Brown | Marketing and Communications Director
alisha@michbio.org | 734-527-9147

Source: Biocom

MORE ON THIS TOPIC